pharmabiz.com

pharmabiz.com
Share

pharmabiz.com

 •  December 26, 2017

US FDA approves Giapreza injection for intravenous infusion to increase blood pressure Silver Spring, Maryland Tuesday, December 26, 2017, 15:00 Hrs [IST] The US Food and Drug Administration (FDA) approved Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure in adults with septic or other distributive...

pharmabiz.com

 •  July 4, 2017

Roche introduces cobas MRSA/SA test to target healthcare-associated infections Basel Tuesday, July 04, 2017, 09:00 Hrs [IST] Roche has announced the CE-IVD launch of the cobas MRSA/SA nucleic acid test for use on the cobas Liat System for the qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and...

pharmabiz.com

 •  February 11, 2017

US FDA approves Access Scientific’s new 3 French, 6 cm Powerwand to eliminate repetitive needlesticks for IV access San Diego Saturday, February 11, 2017, 12:00 Hrs [IST] Access Scientific, LLC, a company dedicated to the development and commercialization of breakthrough, proprietary devices that make vascular access safer for patients and reduce...

pharmabiz.com

 •  February 24, 2016

Following critical evaluation on the use of ranitidine associated with cardiac arrest as per Individual Case Study Reports (ICSRs), the signal review panel (SRP) recently submitted a high level recommendation to the CDSCO suggesting label change of the following medicinal product. They recommended CDSCO to instruct manufacturers and concerned...

pharmabiz.com

 •  August 18, 2015

The US Food and Drug Administration (FDA) has granted Fast Track designation to clinical-stage biotechnology company ContraFect Corporation's CF-301, the first lysin in a new class of medicines, currently in a phase 1 clinical trial, for the treatment of Staph aureus bloodstream infections, including methicillin-resistant Staphylococcus aureus ...

pharmabiz.com

 •  August 8, 2015

BTG plc, an international specialist healthcare company bringing to market innovative products in specialist areas of medicine, announces that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities ...

pharmabiz.com

 •  December 26, 2014

United Therapeutics Corporation, a biotechnology company, announced that Medtronic, Inc. has submitted a pre-market approval application to the US Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin ...

pharmabiz.com

 •  November 3, 2014

Biotronik, a leading manufacturer of cardio and endovascular devices, recently announced the first implantation in the BIOLUX P-III All-Comers Registry. The purpose of this prospective, multi-centre study is to collect and assess safety and efficacy data on the Passeo-18 Lux Drug-Releasing Balloon (DRB) for the treatment of obstructive disease ...